Early Data For Bicycle’s Nectin-4 Asset Shows Promising Duration In Urothelial Cancer
Analysts Cautiously Optimistic
The UK-headquartered biotech’s peptide-toxin conjugate showed a prolonged duration of response in advanced urothelial cancer patients in an early-stage trial compared with current standard of care, raising hopes for a differentiated profile.
